KNIGHT THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.73 CAD | +0.70% |
|
+0.17% | +10.40% |
| Mar. 22 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
| Mar. 21 | Knight Therapeutics Reports Fourth Quarter Results | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,028 | 695.7 | 629.6 | 583.6 | 540.7 | 579.8 | - | - |
| Enterprise Value (EV) 1 | 1,028 | 695.7 | 629.6 | 583.6 | 540.7 | 579.8 | 579.8 | 579.8 |
| P/E ratio | 75.8 x | 16.8 x | 40.8 x | -19.9 x | -32.4 x | 63.7 x | 58.8 x | 45.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 21.7 x | 3.49 x | 2.59 x | 1.99 x | 1.65 x | 1.68 x | 1.64 x | 1.5 x |
| EV / Revenue | 21.7 x | 3.49 x | 2.59 x | 1.99 x | 1.65 x | 1.68 x | 1.64 x | 1.5 x |
| EV / EBITDA | -111 x | 41.3 x | 16.6 x | 10.8 x | 9 x | 9.84 x | 9.22 x | 7.98 x |
| EV / FCF | 229 x | -39.6 x | 15.4 x | 15.5 x | - | 13.5 x | 19.2 x | 15.1 x |
| FCF Yield | 0.44% | -2.53% | 6.48% | 6.44% | - | 7.38% | 5.21% | 6.61% |
| Price to Book | 1.27 x | 0.79 x | 0.74 x | 0.7 x | - | 0.79 x | 0.77 x | 0.8 x |
| Nbr of stocks (in thousands) | 135,629 | 130,035 | 118,786 | 112,672 | 104,187 | 101,187 | - | - |
| Reference price 2 | 7.580 | 5.350 | 5.300 | 5.180 | 5.190 | 5.730 | 5.730 | 5.730 |
| Announcement Date | 3/30/20 | 3/25/21 | 3/24/22 | 3/23/23 | 3/21/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 47.46 | 199.5 | 243.5 | 293.6 | 328.2 | 344.7 | 354.3 | 386.9 |
| EBITDA 1 | -9.244 | 16.84 | 38 | 54.03 | 60.08 | 58.94 | 62.89 | 72.65 |
| EBIT 1 | - | -4.465 | 28.34 | 34.68 | 51.41 | 58.82 | - | - |
| Operating Margin | - | -2.24% | 11.64% | 11.81% | 15.66% | 17.07% | - | - |
| Earnings before Tax (EBT) 1 | 22.78 | 32.08 | 6.69 | -43.96 | -21.99 | 4.886 | 9.774 | 26.66 |
| Net income 1 | 14.52 | 42.07 | 15.68 | -29.89 | -16.84 | 3.972 | 2.8 | 16.9 |
| Net margin | 30.59% | 21.08% | 6.44% | -10.18% | -5.13% | 1.15% | 0.79% | 4.37% |
| EPS 2 | 0.1000 | 0.3190 | 0.1300 | -0.2600 | -0.1600 | 0.0900 | 0.0975 | 0.1267 |
| Free Cash Flow 1 | 4.487 | -17.58 | 40.79 | 37.6 | - | 42.8 | 30.2 | 38.3 |
| FCF margin | 9.45% | -8.81% | 16.75% | 12.81% | - | 12.42% | 8.52% | 9.9% |
| FCF Conversion (EBITDA) | - | - | 107.32% | 69.58% | - | 72.62% | 48.02% | 52.72% |
| FCF Conversion (Net income) | 30.91% | - | 260.2% | - | - | 1,077.63% | 1,078.57% | 226.63% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/25/21 | 3/24/22 | 3/23/23 | 3/21/24 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 73.34 | 58.27 | 63.81 | 75.82 | 72.28 | 81.66 | 82.6 | 89.9 | 81.5 | 74.2 | 79.4 | 90.4 | 87.07 | 87.68 | 85.9 |
| EBITDA 1 | 17.33 | 5.696 | 13.31 | 17.89 | 9.009 | 13.82 | 18.24 | 14.27 | 15.51 | 12.06 | 13.6 | 16.02 | 15.36 | 14.11 | 14.9 |
| EBIT 1 | 15.22 | 2.406 | 10.97 | 13.39 | 2.309 | 8.01 | 16.8 | 11.16 | 12.41 | 11.03 | 14.61 | 15.21 | 14.65 | 14.35 | - |
| Operating Margin | 20.75% | 4.13% | 17.2% | 17.66% | 3.19% | 9.81% | 20.34% | 12.42% | 15.23% | 14.87% | 18.4% | 16.82% | 16.83% | 16.37% | - |
| Earnings before Tax (EBT) 1 | -9.888 | -14.42 | -22.31 | 0.636 | 0.851 | -23.14 | -4.946 | 0.212 | 8.898 | -26.15 | 1.291 | 2.574 | 1.778 | 2.25 | -0.2 |
| Net income 1 | -8.586 | -8.301 | -18.81 | 2.516 | 1.591 | -15.19 | -3.937 | 1.84 | 9.588 | -24.33 | 0.9295 | 1.934 | 1.314 | 1.68 | -0.1 |
| Net margin | -11.71% | -14.25% | -29.48% | 3.32% | 2.2% | -18.6% | -4.77% | 2.05% | 11.76% | -32.79% | 1.17% | 2.14% | 1.51% | 1.92% | -0.12% |
| EPS 2 | -0.0700 | -0.0600 | -0.1600 | 0.0200 | 0.0100 | -0.1300 | -0.0400 | 0.0200 | 0.0900 | -0.2300 | -0.0133 | 0.0200 | 0.006670 | 0.0233 | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 3/24/22 | 5/12/22 | 8/11/22 | 11/10/22 | 3/23/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/21/24 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 4.49 | -17.6 | 40.8 | 37.6 | - | 42.8 | 30.2 | 38.3 |
| ROE (net income / shareholders' equity) | 1.58% | 4.96% | - | -3.58% | - | - | 1.7% | 3.3% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 5.990 | 6.820 | 7.150 | 7.360 | - | 7.210 | 7.420 | 7.150 |
| Cash Flow per Share 2 | 0.0300 | - | - | 0.3500 | - | 0.0100 | 0.2300 | 0.1900 |
| Capex 1 | 0.11 | 5.38 | 224 | 2.89 | - | 10.7 | 10.7 | 10.7 |
| Capex / Sales | 0.23% | 2.7% | 92.08% | 0.98% | - | 3.09% | 3.01% | 2.75% |
| Announcement Date | 3/30/20 | 3/25/21 | 3/24/22 | 3/23/23 | 3/21/24 | - | - | - |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.73
CAD
Average target price
6.729
CAD
Spread / Average Target
+17.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.40% | 424M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- GUD Stock
- Financials Knight Therapeutics Inc.
